The novel mechanism of cancer radioresistance on internal radiation therapy and development of radiosensitizers

癌症放射抗性的内放射治疗新机制及放射增敏剂的开发

• 批准号: 23791463
• 负责人: OHSHIMA Yasuhiro
• 金额: $ 2.83万
• 依托单位: Japan Atomic Energy Agency
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Young Scientists (B)
• 财政年份: 2011
• 资助国家: 日本
• 起止时间: 2011 至 2012
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23791463/
• 关键词: 内用放射線療法; ^<131>I-trastuzumab; ATP; 細胞外ATP 放出; P2 受容体; 放射線抵抗性; P2Y_6 受容体; 放射線増感剤; 131I-trastuzumab; 細胞外ATP放出; P2受容体; P2Y6受容体; 放射線誘発性ATP放出

In this study, we investigated the mechanism of radioresistance through radiation-induced extracellular ATP release and possibility of P2 receptor inhibitor as a novel radiosensitizer. We found extracellular ATP release after treatment of ^<131>I-labeled antibody and an involvement of P2Y_6 receptor in radioresistance. Moreover, we elucidated that the inhibitor of P2Y_6 receptor enhanced growth inhibition of cancer cells induced by ^<131>I-labeled antibody, suggesting P2Y_6 receptor inhibitor as a novel radiosensitizer.

本研究通过辐射诱导细胞外ATP释放来探讨辐射抗性的机制，并探讨P2受体抑制剂作为新型辐射增敏剂的可能性。我们发现，经~（13）I标记的抗体处理后，细胞外ATP的释放<131>和P_2Y_6受体参与了辐射抗性。此外，我们还证实了P2Y_6受体抑制剂增强了~（13）I标记抗体对肿瘤细胞的生长抑制作用<131>，提示P2Y_6受体抑制剂是一种新型的放射增敏剂。